Sort
8,912 grants matching “sars cov 2”
Optimize Formulation of VSA Adjuvant
$600,000David Clements · Adjuvax Llc · N43 · FY2022 · AI
CEIRR: SARS-CoV-2 Research Activities
$600,000Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2021 · AI
IHBEM: Modeling the Impact of Behavioral Feedback on the Transmission of Acute Infectious Diseases
$599,995Kayoko Shioda · Trustees Of Boston University · · FY2023 · MPS
PROJECT 1: IMMUNE MEMORY
$599,917Rafi Ahmed · Emory University · U19 · FY2025 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** CONTAMINATION OF READY-TO-EAT (RTE) FOODS WITH PATHOGENIC MICROORGANISMS CONTINUE TO POSE A SERIOUS RISK TO PUBLIC HEALTH. FOR YEARS, MULTIPLE CASES OF LARGE-SCALE OUTBREAKS AND RECALLS DUE TO ENVIRONMENTAL CONTAMINATION WITH SALMONELLA ENTERICA AND LISTERIA MONOCYTOGENES HAVE BEEN REPORTED. REINFORCEMENT OF CURRENT GOOD MANUFACTURING PRACTICES, IMPLEMENTATION OF NEW FSMA REGULATIONS AND DEPLOYMENT OF NEW INTERVENTION STRATEGIES HAVE YET TO RESULT IN A MARKED REDUCTION IN THE INCIDENCE OF RECALLS AND OUTBREAKS; IT IS THEN CRITICAL TO EXPLORE NOVEL TECHNOLOGICAL STRATEGIES. THE ENVIRONMENTAL CONTAMINATION WITH L. MONOCYTOGENES REPRESENTS A SERIOUS RISK FOR SEVERAL COMMODITIES SUCH AS DAIRY FOODS, FRESH PRODUCE AND FROZEN FOODS AS THIS BACTERIUM IS CAPABLE OF WIDESPREAD CONTAMINATION OF EQUIPMENT AND FACILITIES FOR PACKING AND PROCESSING. S. ENTERICA IS A FOODBORNE PATHOGEN OF CONCERN IN LOW MOISTURE FOODS, POULTRY, MEAT AND PRODUCE AND IS CAPABLE OF PERSISTING ON FOOD CONTACT SURFACES.THE USE OF A DYNAMIC AND HARMLESS LIGHT TECHNOLOGY DURING DOWN TIME AND CLOSE OF OPERATION COULD SERVE AS A USEFUL TOOL IN PREVENTING BIOFILM FORMATION AND PERSISTENCE. ANTIMICROBIAL BLUE LIGHT (ABL) TECHNOLOGY HAS BEEN EXPLORED FOR HOSPITAL DISINFECTION WITH VERY PROMISING RESULTS, BUT ITS APPLICATION TO CONTROL FOODBORNE PATHOGENS REMAINS RELATIVELY LIMITED.THE GOAL OF THIS PROJECT IS TO INVESTIGATE THE APPLICATION OF ABL FOR REDUCING THE SURFACE VIABILITY OF LISTERIA MONOCYTOGENES AND SALMONELLA ENTERICA BIOFILMS, AND OF FOODBORNE ASSOCIATED VIRUSES. SPECIFICALLY, THIS PROJECT WILL: 1) DETERMINE OPTIMAL ABL EMISSION DOSES TO INACTIVATE L. MONOCYTOGENES AND SALMONELLA BIOFILMS AS SINGLE SPECIES ON INERT SOLID SURFACES; 2) ASSESS THE IMPACT OF MIXED CULTURE BIOFILMS ON ABL EFFECTIVENESS TO KILL PATHOGENIC BACTEIRA; 3) DETERMINE OPTIMAL CONDITIONS TO INACTIVATE NOROVIRUS, HEPATITIS A VIRUS AND SARS-COV-2; AND 4) CHARACTERIZE THE POSSIBLE INTERACTION OF ABL WITH SANITIZERS TO INACTIVATEPATHOGEN BIOFILMS. THIS PROJECT WILL INCLUDE A SERIES OF LABORATORY EXPERIMENTS IN WHICH DIFFERENT SURFACES WILL BE INOCULATED WITH PATHOGENIC BACTERIA BIOFILMS AND VIRUSES, ABL-TREATED USING DIFFERENT CONDITIONS AND THE EFFECTIVENESS WILL BE MEASURED BY A COMBINATION OF VIABILITY DETERMINATION AND MICROSCOPY OBSERVATIONS.
$599,900University Of Georgia Research Foundation, Inc. · · FY2022 · National Institute of Food and Agriculture
Project 2VIDA! SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California
$599,874Argentina Elisa Noelle Servin · University Of California, San Diego · R01 · FY2022 · MD
Minimal False-alarm Touch-based Detection of SARS-Cov-2 Virus Particles using Poly-aptamers
$599,859Radislav A Potyrailo · General Electric Global Research Ctr · U01 · FY2022 · AA
Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection
$599,757Linda J. Saif · Ohio State University · U54 · FY2022 · CA
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
$599,601Fred R Hirsch · Icahn School Of Medicine At Mount Sinai · U54 · FY2024 · CA
Adaptive Immunity and Persistent SARS-CoV-2 Replication
$599,569Suresh B Boppana · University Of Alabama At Birmingham · U01 · FY2022 · CA
NIH TCF Dev and Prod of SARS-CoV-2 Spike tetramers for B Cell Detection
$599,404John Altman · Emory University · N01 · FY2020 · AI
Discovery of Isotucaresol derivatives as adjuvants for vaccines testing in a SARS-CoV-2 vaccine model
$598,808Omer Rasheed · Inimmune Corporation · N01 · FY2021 · AI
NICHD Global Network for Womenâs and Childrenâs Health Research: Research Units
$598,766William A Petri · University Of Virginia · UG1 · FY2024 · HD
Multiparametric mapping of Covid-19 immune responses in Kidney transplant recipients
$598,676Peter Scott Heeger · Icahn School Of Medicine At Mount Sinai · U01 · FY2021 · AI
Severity and long-term health effects of COVID-19 among World Trade Center responders
$598,578Olga Morozova · State University New York Stony Brook · U01 · FY2021 · OH
Assessing the long-term impacts of the COVID-19 pandemic on disparities in cancer screening and follow-up
$598,214John F Dickerson · Kaiser Foundation Research Institute · R01 · FY2023 · CA
The longitudinal impact of the COVID-19 pandemic and related multi-level mitigation and contextual factors on health and socioeconomic outcomes of individuals and families from a vulnerable population
$597,961Colter M.s. Mitchell · University Of Michigan At Ann Arbor · U01 · FY2025 · HD
Lipid Bilayer Remodeling and Protein Intermediates During Membrane Fusion
$597,847Kelly Keisen Lee · University Of Washington · R01 · FY2022 · AI
Unraveling Human T Follicular Helper Cell Development
$597,818Philip A Mudd · Washington University · R01 · FY2024 · AI
Rapid and Simple Paper Strip Test for the Multiplexed Detection of Gastrointestinal Pathogens at the Point-of-Need
$597,814Chang Hee Kim · Godx, Inc. · R44 · FY2021 · TR
hHv1 channels in neutrophils and the innate immune inflammatory response
$597,782Steve A N Goldstein · University Of California-Irvine · R01 · FY2025 · HL
Regulation of eicosanoid signaling lipids to improve skeletal muscle function and increase healthspan during aging
$597,186Helen M Blau · Stanford University · R01 · FY2021 · AG
Understanding the Risk of Bat Coronavirus Emergence
$597,112Peter Daszak · Ecohealth Alliance, Inc. · R01 · FY2017 · AI
Brain pathophysiology in SARS-CoV-2 disease
$596,830Kathryn L Sandberg · Georgetown University · R01 · FY2024 · NS
SBIR TOPIC 107 REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON- MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS
$596,519Tori Race · · N43 · FY2022 · AI